A novel splice variant of myd88 and uses thereof
CA 2472927 A1 · Owner: Universiteit Gent · Inventors: Janssens, Sophie; Beyaert, Rudi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the field of infection and inflammation and more specifically to the field of pathogen-induced nuclear factor kappa B activation. More specifically, a novel splice variant of MyD88 (MyD88s), has , been identified encoding a protein that inhibits LPS-induced NF-kappaB activation. MyD88s is a target to inhibit the phenomenon of endotoxintolerance that occurs in sepsis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 10, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 10, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 10, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.